Evaluation of the risk of developing hepatocellular carcinoma in chronic Hepatitis C patients receiving antiviral treatment
Introduction: Chronic HC leads to the development of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). The treatment of chronic HC with DAAs reduces mortality from LC and HCC. The study aimed to investigate the serological markers specific to HCC (PIVKA-II and AFP) in patients with chronic H...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2024-05-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/18410 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850148491197677568 |
|---|---|
| author | Sona Sargsyan Hripsime Magdesieva Tsoghik Navoyan Aregnaz Mkhitaryan Lusine Atoyan Violeta Sargsyan Hayk Harutyunyan Vahe Azatyan Armine Minasyan Naira Gyulazyan |
| author_facet | Sona Sargsyan Hripsime Magdesieva Tsoghik Navoyan Aregnaz Mkhitaryan Lusine Atoyan Violeta Sargsyan Hayk Harutyunyan Vahe Azatyan Armine Minasyan Naira Gyulazyan |
| author_sort | Sona Sargsyan |
| collection | DOAJ |
| description |
Introduction: Chronic HC leads to the development of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). The treatment of chronic HC with DAAs reduces mortality from LC and HCC. The study aimed to investigate the serological markers specific to HCC (PIVKA-II and AFP) in patients with chronic HC before and after DAA treatment.
Methodology: The study involved 35 HCV patients (mean age: 56.23 ± 1.45) divided into two groups. Group 1 included 15 HCV + HCC patients and Group 2 included 20 HCV non-HCC patients.
Results: At the end of treatment all the patients were HCV RNA negative. Three months after the end of antiviral treatment, HCV RNA was undetectable in all patients, while a complete biochemical and virological response was observed in 66.7% of HCV + HCC patients and 85.0% of HCV non-HCC patients. PIVKA-II levels before the initiation of antiviral treatment were high in all patients. At the end of the treatment, in the HCV non-HCC group, normalization of PIVKA-II levels was observed only in 20.0% cases, and in 60.0% of cases 3 months after the treatment. Meanwhile, in patients with HCC and chronic HCV, PIVKA-II levels were within the normal range 3 months after treatment in only 13.3% of patients.
Conclusions: It is necessary to monitor HCV patients with cirrhosis (F4) and severe fibrosis (F3) without HCC, who have high PIVKA-II and AFP levels and/or ALT activity despite obtaining sustained virologic response 3 months after treatment with DAAs.
|
| format | Article |
| id | doaj-art-688588d3149b4fdcab273081f3c94de3 |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-688588d3149b4fdcab273081f3c94de32025-08-20T02:27:14ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802024-05-01180510.3855/jidc.18410Evaluation of the risk of developing hepatocellular carcinoma in chronic Hepatitis C patients receiving antiviral treatmentSona Sargsyan0Hripsime Magdesieva1Tsoghik Navoyan2Aregnaz Mkhitaryan3Lusine Atoyan4Violeta Sargsyan5Hayk Harutyunyan6Vahe Azatyan7Armine Minasyan8Naira Gyulazyan9Yerevan State Medical University (YSMU), Department of Infectious Diseases, Yerevan, ArmeniaYerevan State Medical University (YSMU), Department of Infectious Diseases, Yerevan, ArmeniaYerevan State Medical University (YSMU), Department of Infectious Diseases, Yerevan, ArmeniaYerevan State Medical University (YSMU), Department of Infectious Diseases, Yerevan, ArmeniaYerevan State Medical University (YSMU), Department of Infectious Diseases, Yerevan, Armenia"Violeta” Medical Center, Yerevan, ArmeniaYerevan State Medical University (YSMU), Department of General Surgery, Yerevan, ArmeniaYerevan State Medical University (YSMU), Department of Therapeutic Stomatology, Yerevan, ArmeniaYerevan State Medical University (YSMU), Department of Internal Medicine, Yerevan, ArmeniaYerevan State Medical University (YSMU), Department of Infectious Diseases, Yerevan, Armenia Introduction: Chronic HC leads to the development of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). The treatment of chronic HC with DAAs reduces mortality from LC and HCC. The study aimed to investigate the serological markers specific to HCC (PIVKA-II and AFP) in patients with chronic HC before and after DAA treatment. Methodology: The study involved 35 HCV patients (mean age: 56.23 ± 1.45) divided into two groups. Group 1 included 15 HCV + HCC patients and Group 2 included 20 HCV non-HCC patients. Results: At the end of treatment all the patients were HCV RNA negative. Three months after the end of antiviral treatment, HCV RNA was undetectable in all patients, while a complete biochemical and virological response was observed in 66.7% of HCV + HCC patients and 85.0% of HCV non-HCC patients. PIVKA-II levels before the initiation of antiviral treatment were high in all patients. At the end of the treatment, in the HCV non-HCC group, normalization of PIVKA-II levels was observed only in 20.0% cases, and in 60.0% of cases 3 months after the treatment. Meanwhile, in patients with HCC and chronic HCV, PIVKA-II levels were within the normal range 3 months after treatment in only 13.3% of patients. Conclusions: It is necessary to monitor HCV patients with cirrhosis (F4) and severe fibrosis (F3) without HCC, who have high PIVKA-II and AFP levels and/or ALT activity despite obtaining sustained virologic response 3 months after treatment with DAAs. https://jidc.org/index.php/journal/article/view/18410Chronic HCV infectionhepatocellular carcinomaliver cirrhosisdirect-acting antiviral agents |
| spellingShingle | Sona Sargsyan Hripsime Magdesieva Tsoghik Navoyan Aregnaz Mkhitaryan Lusine Atoyan Violeta Sargsyan Hayk Harutyunyan Vahe Azatyan Armine Minasyan Naira Gyulazyan Evaluation of the risk of developing hepatocellular carcinoma in chronic Hepatitis C patients receiving antiviral treatment Journal of Infection in Developing Countries Chronic HCV infection hepatocellular carcinoma liver cirrhosis direct-acting antiviral agents |
| title | Evaluation of the risk of developing hepatocellular carcinoma in chronic Hepatitis C patients receiving antiviral treatment |
| title_full | Evaluation of the risk of developing hepatocellular carcinoma in chronic Hepatitis C patients receiving antiviral treatment |
| title_fullStr | Evaluation of the risk of developing hepatocellular carcinoma in chronic Hepatitis C patients receiving antiviral treatment |
| title_full_unstemmed | Evaluation of the risk of developing hepatocellular carcinoma in chronic Hepatitis C patients receiving antiviral treatment |
| title_short | Evaluation of the risk of developing hepatocellular carcinoma in chronic Hepatitis C patients receiving antiviral treatment |
| title_sort | evaluation of the risk of developing hepatocellular carcinoma in chronic hepatitis c patients receiving antiviral treatment |
| topic | Chronic HCV infection hepatocellular carcinoma liver cirrhosis direct-acting antiviral agents |
| url | https://jidc.org/index.php/journal/article/view/18410 |
| work_keys_str_mv | AT sonasargsyan evaluationoftheriskofdevelopinghepatocellularcarcinomainchronichepatitiscpatientsreceivingantiviraltreatment AT hripsimemagdesieva evaluationoftheriskofdevelopinghepatocellularcarcinomainchronichepatitiscpatientsreceivingantiviraltreatment AT tsoghiknavoyan evaluationoftheriskofdevelopinghepatocellularcarcinomainchronichepatitiscpatientsreceivingantiviraltreatment AT aregnazmkhitaryan evaluationoftheriskofdevelopinghepatocellularcarcinomainchronichepatitiscpatientsreceivingantiviraltreatment AT lusineatoyan evaluationoftheriskofdevelopinghepatocellularcarcinomainchronichepatitiscpatientsreceivingantiviraltreatment AT violetasargsyan evaluationoftheriskofdevelopinghepatocellularcarcinomainchronichepatitiscpatientsreceivingantiviraltreatment AT haykharutyunyan evaluationoftheriskofdevelopinghepatocellularcarcinomainchronichepatitiscpatientsreceivingantiviraltreatment AT vaheazatyan evaluationoftheriskofdevelopinghepatocellularcarcinomainchronichepatitiscpatientsreceivingantiviraltreatment AT armineminasyan evaluationoftheriskofdevelopinghepatocellularcarcinomainchronichepatitiscpatientsreceivingantiviraltreatment AT nairagyulazyan evaluationoftheriskofdevelopinghepatocellularcarcinomainchronichepatitiscpatientsreceivingantiviraltreatment |